Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

SHOCKING: Immunovant q4 earnings call highlights - What They Never Told You

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.

Matthew Klein, CEO of Roivant, said the company has had “a pretty wild 12 months,” citing progress across multiple programs and a series of expected milestones over the next year. The most prominent update was preliminary open-label data from a study of IMVT-1402 in difficult-to-treat rheumatoid arthritis, a program run by Immunovant (NASDAQ:IMVT).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.